home / stock / fgen / fgen quote
Last: | $1.07 |
---|---|
Change Percent: | -0.88% |
Open: | $1.15 |
Close: | $1.07 |
High: | $1.26 |
Low: | $1.05 |
Volume: | 1,337,984 |
Last Trade Date Time: | 04/23/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.07 | $1.15 | $1.07 | $1.26 | $1.05 | 1,337,984 | 04-23-2024 |
$1.14 | $1.15 | $1.14 | $1.17 | $1.08 | 803,876 | 04-22-2024 |
$1.15 | $1.16 | $1.15 | $1.18 | $1.05 | 1,312,940 | 04-19-2024 |
$1.17 | $1.26 | $1.17 | $1.29 | $1.14 | 1,278,178 | 04-18-2024 |
$1.27 | $1.3 | $1.27 | $1.33 | $1.24 | 1,031,441 | 04-17-2024 |
$1.3 | $1.28 | $1.3 | $1.35 | $1.25 | 863,694 | 04-16-2024 |
$1.31 | $1.3 | $1.31 | $1.37 | $1.24 | 1,265,440 | 04-15-2024 |
$1.3 | $1.35 | $1.3 | $1.35 | $1.23 | 1,140,382 | 04-12-2024 |
$1.36 | $1.45 | $1.36 | $1.465 | $1.35 | 1,161,885 | 04-11-2024 |
$1.43 | $1.49 | $1.43 | $1.51 | $1.36 | 1,355,936 | 04-10-2024 |
$1.51 | $1.62 | $1.51 | $1.63 | $1.485 | 1,013,966 | 04-09-2024 |
$1.63 | $1.63 | $1.63 | $1.69 | $1.56 | 1,197,536 | 04-08-2024 |
$1.62 | $1.56 | $1.62 | $1.695 | $1.51 | 1,620,188 | 04-05-2024 |
$1.58 | $1.41 | $1.58 | $1.815 | $1.385 | 4,160,869 | 04-04-2024 |
$1.47 | $2.14 | $1.47 | $2.15 | $1.1801 | 10,341,438 | 04-03-2024 |
$2.16 | $2.28 | $2.16 | $2.33 | $2.1 | 932,124 | 04-02-2024 |
$2.36 | $2.35 | $2.36 | $2.3975 | $2.17 | 1,275,625 | 04-01-2024 |
$2.35 | $2.58 | $2.35 | $2.59 | $2.31 | 1,357,227 | 03-29-2024 |
$2.35 | $2.58 | $2.35 | $2.59 | $2.31 | 1,357,227 | 03-28-2024 |
$2.58 | $2.46 | $2.58 | $2.68 | $2.3 | 1,846,414 | 03-27-2024 |
News, Short Squeeze, Breakout and More Instantly...
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Re...
FibroGen Inc (NASDAQ:FGEN) announced topline data from the Fortis Therapeutics-sponsored Phase 1 study of FG-3246 (also known as FOR46), a pot...
FG-3246 demonstrated efficacy in adenocarcinoma selected cohorts receiving biologically active doses of FG-3246 at ≥ 1.2 mg/kg in heavily pre-treated, biomarker unselected patients: Median radiographic progression free survival of 8.7 months PSA50 response in 36% ...